Trial Profile

Multi-cohort, Open, Phase II Clinical Study of TQB2868 Injection Combined With Arotinib Capsule and Chemotherapy in the First-line Treatment of Pancreatic Neoplasms

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; TQB 2868 (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical

Most Recent Events

19 Sep 2025 The protocol has been amended to addition in treatment arm size, Interventional Study Model changed from Single Group Assignment to Parallel Assignment and Allocation is changed Non-Randomized.
19 Sep 2025 Planned number of patients changed from 50 to 80.
19 Sep 2025 Planned End Date changed from 1 Oct 2025 to 1 Nov 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com